APR 18, 2020 4:14 PM PDT

A New Double Threat Against Skin Cancer

WRITTEN BY: Jasper Cantrell

Skin cancer is one of the most common cancers in America. One of the most aggressive forms of skin cancer is melanoma, accounting for up to 85% of skin cancer deaths and a poor two-year prognosis. A few treatments are available, from chemotherapy to immunotherapy; however, the prognosis remains grim. A group from China decided to investigate an up and coming chemotherapy, alteronol, against melanoma. In particular, they were curious as to how it’s of autophagic activity might affect its anti-cancer activities.

Alteronol is a drug that has the same origins as another frontline chemotherapy Paclitaxel. Previous research has found it to be effective against many cancers, including melanoma. The primary activities that give it its anti-tumor abilities revolve around inducing apoptosis in cancer cells, as well as preventing metastasis through suppressing cellular migration. One of its lesser-known activities is autophagy, which conversely is linked to cancer progression. Alteronol’s autophagy activity would, therefore, be a target for study.

Using melanoma cell lines, they found that the addition of alteronol preferentially hindered the growth of cancer cells over normal cells. Alteronol’s apoptotic activity was confirmed by measuring levels of apoptotic proteins upon its application. The group then began looking at the Akt/mTOR pathway as a possible reason for alteronol’s autophagic activities. The Akt/mTOR is a known regulatory pathway of autophagy, and it was found that alteronol seemed to suppress its activation. This observation led the team to introduce a second drug, 3-MA, to prevent this suppression. The addition of both alteronol and 3-MA unexpectedly showed higher apoptotic activity. This dual treatment also enhanced alteronol’s inhibition of cellular migration and invasion. Wrapping it all together, the group ran mouse experiments that confirmed that while alteronol alone could decrease tumor growth, the dual treatment was shown to be an even greater suppresser of tumor growth.

The prevalence of skin cancer makes the poor prognosis of its most aggressive form a frightening concept. With prevention with sunscreen and regular checkups having the best results, treatments for skin cancer itself are comparably ineffective. Therefore, the dual treatment found from this investigation could be a literal lifesaver. The group concludes, “Our results demonstrated that alteronol is an effective anti-melanoma agent both in vitro and in vivo, and the combination of alteronol and autophagy inhibitor 3-MA may have multiple beneficial effects as a potential treatment for melanoma.”

Sources: Nature, Mayo Clinic

About the Author
Bachelors of the Sciences
Hey everyone! My name is Jasper and, considering I am pretty new here to Labroots, I figured I would introduce myself. I received my bachelor’s from the University of California at Riverside back in 2016. I started off my career a few years ago with a job at a University over in New York, before moving over into the industry. I'm happy to be writing content for Labroots, and I hope you enjoy it!
You May Also Like
JUL 11, 2022
Cancer
Boosting CAR T Cell Therapy with TIGIT Blockade
JUL 11, 2022
Boosting CAR T Cell Therapy with TIGIT Blockade
Chimeric antigen receptor (CAR) T Cell therapy has emerged as a promising immunotherapeutic approach to treat blood canc ...
JUL 25, 2022
Cell & Molecular Biology
Cancer Cells Migrate To 'Softer' Spots
JUL 25, 2022
Cancer Cells Migrate To 'Softer' Spots
The environments surrounding cancer cells are thought to promote cancer growth. Researchers have previously shown that c ...
AUG 18, 2022
Clinical & Molecular DX
New Research Investigates the Molecular Spread of Triple-Negative Breast Cancer
AUG 18, 2022
New Research Investigates the Molecular Spread of Triple-Negative Breast Cancer
Triple-negative breast cancer (TNBC) accounts for 10-15% of all breast cancer cases. TNBC is a term used to describe cas ...
SEP 28, 2022
Drug Discovery & Development
Impact of In Vivo Controls on Therapeutic Drug Development
SEP 28, 2022
Impact of In Vivo Controls on Therapeutic Drug Development
The significance of antibody based in vivo studies   For both research and therapeutic purposes, antibodies ca ...
OCT 18, 2022
Immunology
Cell Adhesion Molecules in Immune and Cancer Therapy
OCT 18, 2022
Cell Adhesion Molecules in Immune and Cancer Therapy
Introduction The immune system plays a dual role in inflammation and cancer development. Immune system effector cells ra ...
NOV 23, 2022
Technology
Hyperthermic Nanoparticles for Cancer Treatment
NOV 23, 2022
Hyperthermic Nanoparticles for Cancer Treatment
Hyperthermia (excess heats) refers to the use of high temperatures to treat cancer. When used to treat tumors locally, h ...
Loading Comments...